Nurse-Led Medicines' Monitoring for Patients with Dementia in Care Homes: A Pragmatic Cohort Stepped Wedge Cluster Randomised Trial

Susan Jordan, Marie Ellenor Gabe-Walters, Alan Watkins, Ioan Humphreys, Louise Newson, Sherrill Snelgrove, Michael S Dennis, Susan Jordan, Marie Ellenor Gabe-Walters, Alan Watkins, Ioan Humphreys, Louise Newson, Sherrill Snelgrove, Michael S Dennis

Abstract

Background: People with dementia are susceptible to adverse drug reactions (ADRs). However, they are not always closely monitored for potential problems relating to their medicines: structured nurse-led ADR Profiles have the potential to address this care gap. We aimed to assess the number and nature of clinical problems identified and addressed and changes in prescribing following introduction of nurse-led medicines' monitoring.

Design: Pragmatic cohort stepped-wedge cluster Randomised Controlled Trial (RCT) of structured nurse-led medicines' monitoring versus usual care.

Setting: Five UK private sector care homes.

Participants: 41 service users, taking at least one antipsychotic, antidepressant or anti-epileptic medicine.

Intervention: Nurses completed the West Wales ADR (WWADR) Profile for Mental Health Medicines with each participant according to trial step.

Outcomes: Problems addressed and changes in medicines prescribed.

Data collection and analysis: Information was collected from participants' notes before randomisation and after each of five monthly trial steps. The impact of the Profile on problems found, actions taken and reduction in mental health medicines was explored in multivariate analyses, accounting for data collection step and site.

Results: Five of 10 sites and 43 of 49 service users approached participated. Profile administration increased the number of problems addressed from a mean of 6.02 [SD 2.92] to 9.86 [4.48], effect size 3.84, 95% CI 2.57-4.11, P <0.001. For example, pain was more likely to be treated (adjusted Odds Ratio [aOR] 3.84, 1.78-8.30), and more patients attended dentists and opticians (aOR 52.76 [11.80-235.90] and 5.12 [1.45-18.03] respectively). Profile use was associated with reduction in mental health medicines (aOR 4.45, 1.15-17.22).

Conclusion: The WWADR Profile for Mental Health Medicines can improve the quality and safety of care, and warrants further investigation as a strategy to mitigate the known adverse effects of prescribed medicines.

Trial registration: ISRCTN 48133332.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1. Numbers in the analysis.
Fig 1. Numbers in the analysis.
Fig 2. The medication chain.
Fig 2. The medication chain.

References

    1. National Patient Safety Agency (NPSA). Safety in doses: medication safety incidents in the NHS National Patient Safety Agency, London: 2007.
    1. Committee of Public Accounts. A Safer Place for Patients: Learning to Improve Patient Safety. London, UK: The Stationery Office, 2006.
    1. Francis R. Report of the Mid Staffordshire NHS Foundation Trust Public Inquiry: Executive Summary. (Online). Available: Accessed 4 June 2015.
    1. Andrews J, Butler M. Trusted to Care An independent Review of the Princess of Wales Hospital and Neath Port Talbot Hospital at Abertawe Bro Morgannwg University Health Board People, Dementia Services Development Centre, the People Organisation. 2014. Available: Accessed 4 June 2015.
    1. Jordan S, Kyriacos U. Medicines’ Management: a public health problem on nursing’s agenda. Journal of Nursing Management. 2014; 22(3):271–5 10.1111/jonm.12238
    1. Gabe M, Murphy F, Davies G, Davies M, Johnstone L, Jordan S. Adverse events and nurse-led medication monitoring. Journal of Nursing Management 2011; 19, 377–392
    1. International Conference on Harmonisation (ICH) ICH Harmonised Tripartite Guideline for Good Clinical Practice. Institute of Clinical Research, Marlow, Buckinghamshire. 1996. Available: . Accessed 4 June 2015.
    1. Davies EC, Green CF, Mottram DR, Rowe PH, Pirmohamed M. Emergency re-admissions to hospital due to adverse drug reactions within 1 year of the index admission. British Journal of Clinical Pharmacology. 2010; 70 (5), 749–55. 10.1111/j.1365-2125.2010.03751.x
    1. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004; 329(7456), 15–19.
    1. Marcum ZA, Amuan ME, Hanlon JT, Aspinall SL, Handler SM, Ruby CM, et al. Prevalence of unplanned hospitalizations caused by adverse drug reactions in older veterans. Journal of the American Geriatric Society. 2012; 60 (1), 34–41. 10.1111/j.1532-5415.2011.03772.x
    1. Howard R, Avery A, Slavenburg S, Royal S, Pipe G, Lucassen P, et al. Which drugs cause preventable admissions to hospital? A systematic review. Bristish Journal of Clinical Pharmacology. 2007; 63 (2), 136–47.
    1. Wu TY, Jen MH, Bottle A, Molokhia M, Aylin P, Bell D, et al. Ten-year trends in hospital admissions for adverse drug reactions in England 1999–2009. Journal of the Royal Society of Medicine.2010; 103 (6), 239–50. 10.1258/jrsm.2010.100113
    1. Frontier Economic. Exploring the costs of unsafe care in the NHS: a report prepared for the department of health, Frontier Economics, London: 2014. Available: . Accessed 4 June 2015.
    1. Sultana J, Cutroneo P, Trifirò G. Clinical and economic burden of adverse drug reactions. Journal of Pharmacology and Pharmacotherapeutics. 2013; 4 (Suppl1), S73–S77.
    1. NICE Medicines & Prescribing Centre. Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes NICE guideline 5. NICE, London: 2015. Available: Accessed 4 June 2015.
    1. Hakkarainen KM, Andersson Sundell K, Petzold M, Hägg S. Prevalence and perceived preventability of self-reported adverse drug events-a population-based survey of 7099 adults. PLoS ONE. 2013; 8 (9), e73166 10.1371/journal.pone.0073166
    1. Forster AJ, Murff HJ, Peterson JF, Gandhi TJ, Bates TW. Adverse drug events occurring following hospital discharge. Journal of General Internal Medicine 2005; 20(4) pp.317–323.
    1. Gurwitz J, Field T, Judge J, Rochon P, Harrold LR, Cadoret C, et al. The incidence of adverse drug events in two large academic long-term care facilities. The American Journal of Medicine 2005; 118, 251–8
    1. Alldred DP, Raynor DK, Hughes C, Barber N, Chen TF, Spoor P. Interventions to optimise prescribing for older people in care homes. Cochrane Database of Systematic Reviews 2013; Issue 2 Art. No.: CD009095 10.1002/14651858.CD009095.pub2
    1. Steinman MA, Handler SM, Schiff GD, Covinsky KE. Beyond the prescription: medication monitoring and adverse drug events in older adults. 2011; 59(8) pp. 1513–20.
    1. Brenner S, Detz A, López A, Horton C, Sarkar U. Signal and noise: applying a laboratory trigger tool to identify adverse drug events among primary care patients. BMJ Qual Saf. 2012; 21(8):670–5. 10.1136/bmjqs-2011-000643
    1. Jordan S. Managing Adverse Drug Reactions: An Orphan Task. Developing nurse-administered evaluation checklists. Journal of Advanced Nursing 2002; 38:5: 437–448.
    1. Jordan S, Tunnicliffe C, Sykes A. Minimising Side Effects: The clinical impact of nurse-administered ‘side effects’ checklists. Journal of Advanced Nursing 2002; 37;2:155–65.
    1. Jordan S, Gabe M, Newson L, Snelgrove S, Panes G, Picek A, et al. Medication Monitoring for People with Dementia in Care Homes: the Feasibility and Clinical Impact of Nurse-led monitoring. The Scientific World Journal, vol. 2014, Article ID 843621, 11 pages, 10.1155/2014/843621
    1. Gabe ME, Murphy F, Davies GA, Russell IT, Jordan S. Medication monitoring in a nurse-led respiratory outpatient clinic: pragmatic randomised trial of the West Wales Adverse Drug Reaction Profile. PLOS One 2014;9(5) e96682 10.1371/journal.pone.0096682
    1. Banerjee S. The use of antipsychotic medication for people with dementia: time for action. A report for the Minister of State for Care Services. An Independent |Report commissioned for the Department of Health, London 2009. Available: . Accessed 4 June 2015.
    1. Child A, Clarke A, Fox C, Maidment I. A pharmacy led program to review anti-psychotic prescribing for people with dementia. BMC Psychiatry. 2012;12:155 10.1186/1471-244X-12-155
    1. Alessi-Severini S, Dahl M, Schultz J, Metge C, Raymond C. Prescribing of psychotropic medications to the elderly population of a Canadian province: a retrospective study using administrative databases. PeerJ, 2013;1, e168 10.7717/peerj.168
    1. Harris T, Carey IM, Shah SM, DeWilde S, Cook DG. Antidepressant prescribing in older primary care patients in community and care home settings in England and Wales. J Am Med Dir Assoc. 2012;13(1):41–7. 10.1016/j.jamda.2010.09.005
    1. Stefan H. Epilepsy in the elderly: facts and challenges. Acta Neurol Scand. 2011; 124(4):223–37. 10.1111/j.1600-0404.2010.01464.x
    1. Laroche ML, Perault-Pochat MC, Ingrand I, Merle L, Kreft-Jais C, Castot-Villepelet A, et al. Adverse drug reactions in patients with Alzheimer's disease and related dementia in France: a national multicentre cross-sectional study. Pharmacoepidemiol Drug Saf. 2013. September;22(9):952–60. 10.1002/pds.3471 Epub 2013 Jun 24.
    1. Gallini A, Andrieu S, Donohue JM, Oumouhou N, Lapeyre-Mestre M, Gardette V. Trends in use of antipsychotics in elderly patients with dementia: Impact of national safety warnings. Eur Neuropsychopharmacol. 2014 January;24(1):95–104. 10.1016/j.euroneuro.2013.09.003
    1. FDA. Information for Healthcare Professionals: Conventional Antipsychotics. 2008. Available: . Accessed 4 June 2015.
    1. British National Formulary. BNF number 69. London, UK: British Medical Association and the Royal Pharmaceutical Society of Great Britain; 2015.
    1. NICE. Psychosis and Schizophrenia in adults: treatment and interventions management of schizophrenia in primary and secondary care (update). Clinical Practice Guideline no. 178. Centre for Clinical Practice. Commissioned by NICE. 2014. Available: . Accessed 4 June 2015.
    1. Raynor DK, Blenkinsopp A, Knapp P, Grime J, Nicolson DJ, Pollock K, et al. A systematic review of quantitative and qualitative research on the role and effectiveness of written information available to patients about individual medicines. Health Technol Assess. 2007;11(5):iii, 1–160.
    1. Nicolson D, Knapp P, Raynor DK, Spoor P. Written information about individual medicines for consumers. Cochrane Database Syst Rev. 2009;(2):CD002104 10.1002/14651858.CD002104.pub3
    1. Grant AM, Guthrie B, Dreischulte T. Developing a complex intervention to improve prescribing safety in primary care: mixed methods feasibility and optimisation pilot study. BMJ Open. 2014;4 (1), e004153 10.1136/bmjopen-2013-004153
    1. RESPECT Trial Team. Effectiveness of shared pharmaceutical care for older patients: RESPECT trial findings. Br J Gen Pract 2009; 10.3399/bjgp09X473295 (abridged text, in print: Br J Gen Pract 2010; 59: 14–20).
    1. Forsetlund L, Eike MC, Gjerberg E, Vist GE. Effect of interventions to reduce potentially inappropriate use of drugs in nursing homes: a systematic review of randomised controlled trials. BMC Geriatr. 2011;11:16 10.1186/1471-2318-11-16
    1. Holland R, Desborough J, Goodyer L, Hall S, Wright D, Loke YK. Does pharmacist-led medication review help to reduce hospital admissions and deaths in older people? A systematic review and meta-analysis. Br J Clin Pharmacol. 2008;65(3):303–16.
    1. Jordan S, Knight J, Pointon D. Monitoring adverse drug reactions: scales, profiles, and checklists. International nursing review, 2004;51(4), 208–221.
    1. Bakerjian D. CMS national partnership to improve dementia care in nursing homes Geriatric Nursing. 2014;35 (1), 77–79
    1. Woertman W, de Hoop E, Moerbeek M, Zuidema SU, Gerritsen DL, Teerenstra S. Stepped wedge designs could reduce the required sample size in cluster randomized trials. Journal of Clinical Epidemiology. 2013;66(7) 752–758. 10.1016/j.jclinepi.2013.01.009
    1. Brown CA, Lilford RJ. The stepped wedge trial design: a systematic review. BMC Medical Research Methodology 2006;6:54
    1. Keriel-Gascou M, Buchet-Poyau K, Duclos A, Rabilloud M, Figon S, Dubois JP, et al. Evaluation of an interactive program for preventing adverse drug events in primary care: study protocol of the InPAct cluster randomised stepped wedge trial. Implementation Science. 2013;8:69 10.1186/1748-5908-8-69
    1. Mdege ND, Man MS, Taylor Nee Brown CA, Torgerson DJ. Systematic review of stepped wedge cluster randomized trials shows that design is particularly used to evaluate interventions during routine implementation. J Clin Epidemiol. 2011;64(9):936–48. 10.1016/j.jclinepi.2010.12.003
    1. Campbell MK, Piaggio G, Elbourne DR, Altman DG, CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661 10.1136/bmj.e5661
    1. National Quality Forum MCC Measurement Framework Final Report, Washington DC. 2012. Available: . Accessed 4 June 2015.
    1. Jordan S, Hardy B, Coleman M. Medication management: an exploratory study into the role of Community Mental Health Nurses. Journal of Advanced Nursing. 1999:29:5: 1068–81
    1. Jordan S, Jones R, Sargeant M. Adverse drug reactions: managing the risk. Journal of Nursing Management. 2009;17; 175–84 10.1111/j.1365-2834.2009.00977.x
    1. Jordan S. The Prescription Drug Guide for Nurses. Open University Press, McGraw-Hill, Maidenhead: 2008.
    1. Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guidelines, 11th Edition, Wiley Blackwell, Oxford: 2012.
    1. Uitenbroek DG. "SISA-Binomial" (Simple Interactive Statistical Analysis). 1997. SISA. Available: . Accessed 4 June 2015.
    1. Killip S, Mahfoud Z, Pearce K. What Is an Intracluster Correlation Coeffi cient? Crucial Concepts for Primary Care Researchers. Annals of Family Medicine 2004;2(3):204–08
    1. Hussey MA, Hughes JP. Design and analysis of stepped wedge cluster randomized trials. Contemp Clin Trials. 2007;28(2):182–91.
    1. Husebo BS, Ballard C, Sandvik R, Nilsen OB, Aarsland D. Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. BMJ. 2011;343:d4065 10.1136/bmj.d4065
    1. French DD, Campbell R, Spehar A, Cunningham F, Foulis P. (2005) Outpatient Medications and Hip Fractures in the US: A National Veterans Study. Drugs and Aging. Vol. 22(10) pp. 877–885.
    1. van Doorn C, Gruber-Baldini A, Zimmermann S, Hebel JR, Port CL, Baumgarten M, et al. Dementia as a risk factor for falls and fall injuries among nursing home residents. Journal of the American Geriatrics Society 2003; 51: 1213–1218
    1. Sørensen HJ, Jensen SO, Nielsen J. Schizophrenia, antipsychotics and risk of hip fracture: a population-based analysis. Eur Neuropsychopharmacol. 2013;23(8):872–8. 10.1016/j.euroneuro.2013.04.002 Epub 2013 May 1. .
    1. Rosenberg PB, Mielke MM, Han D, Leoutsakos JS, Lyketsos CG, Rabins PV, et al. The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease. International journal of geriatric psychiatry, 2012;27(12), 1248–1257. 10.1002/gps.3769
    1. Barry HE, Parsons C, Passmore AP, Hughes CM. Pain in care home residents with dementia: an exploration of frequency, prescribing and relatives' perspectives. Int J Geriatr Psychiatry 2015;30(1):55–63. 10.1002/gps.4111
    1. Bucks RS, Ashworth DL, Wilcock GK, Siegfried K. Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale. Age and Ageing 1996;25: 113–120.
    1. Allen NH, Gordon S, Hope T, Burns A. Manchester and Oxford Universities Scale for the Psychopathological Assessment of Dementia (MOUSEPAD). The British Journal of Psychiatry, 1996;169(3), 293–307.
    1. Act, Mental Capacity. The Stationery Office. 2005.
    1. Weijer C, Grimshaw JM, Eccles MP, McRae AD, White A, Brehaut JC, et al. Ottawa Ethics of Cluster Randomized Trials Consensus Group. The Ottawa Statement on the Ethical Design and Conduct of Cluster Randomized Trials. PLoS Med. 2012;9(11):e1001346.
    1. Diazordaz K, Slowther AM, Potter R, Eldridge S. Consent processes in cluster-randomised trials in residential facilities for older adults: a systematic review of reporting practices and proposed guidelines. BMJ Open. 2013;3(7). pii: e003057 10.1136/bmjopen-2013-003057
    1. Council of International Organisations of Medical Sciences (CIOMS). International Ethical Guidelines for Biomedical Research Involving Human Subjects. Published in Geneva, Switzerland. 2002. Available: . Accessed 4 June 2015.
    1. Curtis L PSSRU (Personal Social Services Research Unit) Unit Costs 2013. Available: . Accessed 4 June 2015.
    1. NHS Reference Costs 2012/2013. Available: Accessed 5 June 2015.
    1. Bakken MS, Engeland A, Engesæter LB, Ranhoff AH, Hunskaar S, Ruths S. Risk of hip fracture among older people using anxiolytic and hypnotic drugs: a nationwide prospective cohort study. Eur J Clin Pharmacol. 2014. July;70(7):873–80. 10.1007/s00228-014-1684-z
    1. European Commission. Objective 1: Supporting development in less prosperous regions. 2008. Available: Accessed 4 June 2015.
    1. Barber ND, Alldred DP, Raynor DK, Dickinson R, Garfield S, Jesson B, et al. Care homes' use of medicines study: prevalence, causes and potential harm of medication errors in care homes for older people. Qual Saf Health Care. 2009;18(5):341–6. 10.1136/qshc.2009.034231
    1. Jordan S, Coleman M, Hardy B, Hughes D. Assessing Educational Effectiveness: The impact of a specialist course on the delivery of care. Journal of Advanced Nursing 1999;30:4:796–807.
    1. Jordan S, Watkins A, Storey M, Allen SJ, Brooks CJ, Garauova I, et al. Volunteer Bias in Recruitment, Retention, and Blood Sample Donation in a Randomised Controlled Trial Involving Mothers and Their Children at Six Months and Two Years: A Longitudinal Analysis. PLoS ONE. 2013;8(7): e67912
    1. Puffer S, Torgerson D, Watson J. Evidence for risk of bias in cluster randomised trials: review of recent trials published in three general medical journals. BMJ. 2003;327(7418):785–9.
    1. McIntosh J, Stellenberg EL. Effect of a staffing strategy based on voluntary increase in working hours on quality of patient care in a hospital in KwaZulu-Natal Curations 2009;3:(2): 1 1–2 0
    1. Hwang YJ, Dixon SN, Reiss JP, Wald R, Parikh CR, Gandhi S, et al. Atypical antipsychotic drugs and the risk for acute kidney injury and other adverse outcomes in older adults: a population-based cohort study. Ann Intern Med. 2014;161(4):242–8. 10.7326/M13-2796
    1. Roethlisberger FS, Dickson WJ. Management and the Worker. Harvard University Press, Cambridge, Massachusetts: 1939.
    1. Sackett DL. Bias in analytic research. Journal of Chronic Diseases, 1979;32(1), 51–63.
    1. Sackett D, Haynes RB, Guyatt G, Tugwell P. Clinical Epidemiology: A Basic Science For Clinical Medicine, 2nd ed Little, Brown, Boston, MA: 1991.
    1. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P, CONSORT Group. Extending the CONSORT Statement to Randomized Trials of Nonpharmacological Treatment: Explanation and Elaboration. Annals of Internal Medicine. 2008;148: 295–309.
    1. Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ 2008;337: a2390 pp. 1223–1226. 10.1136/bmj.a2390
    1. Hróbjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Hilden J, Boutron I, et al. Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. BMJ 2012;344: e1119 10.1136/bmj.e1119
    1. Rosenthal R, Jacobson L. Teachers' expectancies: Determinants of pupils' IQ gains. Psychological Reports, 1963;19, 115–118
    1. Higgins JPT, Altman DG, Sterne JAC. (editors). Assessing risk of bias in included studies Chapter 8 In: Higgins J.P.T., Green S. (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available: . Accessed 4 June 2015.
    1. Schulz K, Grimes DA. The Lancet handbook of essential concepts in clinical research. Edinburgh: Elsevier; 2006.
    1. Keogh-Brown MR, Bachmann MO, Shepstone L, Hewitt C, Howe A, Ramsay CR, et al. Contamination in trials of education interventions. Health technology Assessment 2007;11(43): iii, ix–107.
    1. Christensen M, Lundh A. Medication review in hospitalised patients to reduce morbidity and mortality. Cochrane Database Syst Rev. 2013;28;2:CD008986.
    1. Pacini M, Smith RD, Wilson EC, Holland R. Home-based medication review in older people: is it cost effective? Pharmacoeconomics. 2007;25(2):171–80.
    1. Bosboom PR, Alfonso H, Almeida OP, Beer C. Use of Potentially Harmful Medications and Health-Related Quality of Life among People with Dementia Living in Residential Aged Care Facilities. Dement Geriatr Cogn Dis Extra. 2012;2(1):361–71. 10.1159/000342172
    1. Zermansky AG, Alldred DP, Petty DR, Raynor DK, Freemantle N, Eastaugh J, et al. Clinical medication review by a pharmacist of elderly people living in care homes—randomised controlled trial. Age and ageing, 2006;35(6), 586–591.
    1. Patterson SM, Hughes C, Kerse N, Cardwell CR, Bradley MC. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev, 2012;5(5).
    1. Viswanathan M, Kahwati LC, Golin CE, Blalock SJ, Coker-Schwimmer E, Posey R, et al. Medication Therapy Management Interventions in Outpatient Settings: A Systematic Review and Meta-analysis. JAMA Intern Med. 2014; 10.1001/jamainternmed.2014.5841 [Epub ahead of print]
    1. Watson-Wolfe K, Galik E, Klinedinst J, Brandt N. Application of the Antipsychotic Use in Dementia Assessment audit tool to facilitate appropriate antipsychotic use in long term care residents with dementia. Geriatric Nursing, 2014;35(1), 71–76. 10.1016/j.gerinurse.2013.09.002
    1. Nkansah N, Mostovetsky O, Yu C, Chheng T, Beney J, Bond CM, et al. Effect of outpatient pharmacists' non-dispensing roles on patient outcomes and prescribing patterns. Cochrane Database Syst Rev. 2010;(7):CD000336 10.1002/14651858.CD000336.pub2
    1. Topinková E, Baeyens JP, Michel JP, Lanq PO. Evidence-based strategies for the optimization of pharmacotherapy in older people. Drugs Aging. 2012;29(6):477–94. 10.2165/11632400-000000000-00000
    1. Lapane KL, Hughes CM, Daiello LA, Cameron KA, Feinberg J. Effect of a pharmacist-led multicomponent intervention focusing on the medication monitoring phase to prevent potential adverse drug events in nursing homes. J Am Geriatr Soc. 2011;59(7):1238–45. 10.1111/j.1532-5415.2011.03418.x
    1. Arditi C, Rège-Walther M, Wyatt JC, Durieux P, Burnand B. Computer-generated reminders delivered on paper to healthcare professionals; effects on professional practice and health care outcomes. Cochrane Database of Systematic Reviews 2012; Issue 12 Art. No.: CD001175 10.1002/14651858.CD001175.pub3
    1. Vigen CLP, Mack WJ, Keefe RSE, Sano M, Sultzer D, Stroup S, et al. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's Disease: Outcomes From CATIE-AD. The American Journal of Psychiatry 2011;168(8)pp.831–839. 10.1176/appi.ajp.2011.08121844
    1. Seitz DP, Gill SS, Herrmann N, Brisbin S, Rapoport MJ, Rines J, et al. Pharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review. International Psychogeriatrics, 2013;25(02), 185–203.
    1. American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60:616–31 10.1111/j.1532-5415.2012.03923.x
    1. Murray-Thomas T, Jones ME, Patel D, Brunner E, Shatapathy CC, Motsko S, et al. Risk of mortality (including sudden cardiac death) and major cardiovascular events in atypical and typical antipsychotic users: a study with the general practice research database. Cardiovasc Psychiatry Neurol. 2013;2013:247486 10.1155/2013/247486
    1. Corbett A, Burns A, Ballard C. Don’t use antipsychotics routinely to treat agitation and aggression in people with dementia. BMJ 2014;349; g6420 10.1136/bmj.g6420
    1. Bradley MC, Motterlini N, Padmanabhan S, Cahir C, Williams T, Fahey T, et al. Potentially inappropriate prescribing among older people in the United Kingdom. BMC Geriatr. 2014;14:72 10.1186/1471-2318-14-72
    1. Hall SA, Maserejian NN, Link CL, Steers WD, McKinlay JB. Are commonly used psychoactive medications associated with lower urinary tract symptoms? Eur J Clin Pharmacol. 2012;68(5):783–91. 10.1007/s00228-011-1170-9
    1. Maughan RJ. Hydration, morbidity, and mortality in vulnerable populations. Nutr Rev. 2012;70 Suppl 2:S152–5. 10.1111/j.1753-4887.2012.00531.x
    1. Manz F, Wentz A. The importance of good hydration for the prevention of chronic diseases. Nutrition reviews, 2005;63(s1), S2–S5.
    1. Aronson JK. (ed.) Meyler's Side Effects of Drugs: The International Encyclopaedia of Adverse Drug Reactions and Interactions. Amsterdam, Elsevier; 2006.
    1. Golder S, Loke Y. Search strategies to identify information on adverse effects: a systematic review. Journal of the Medical Library Association 2009;97(2): 84–92. 10.3163/1536-5050.97.2.004
    1. Tsang R, Colley L, Lynd LD. Inadequate statistical power to detect clinically significant differences in adverse event rates in randomized controlled trials. Journal of Clinical Epidemiology 2009;62: 609–16. 10.1016/j.jclinepi.2008.08.005
    1. Zorzela L, Golder S, Liu Y, Pilkington K, Hartling L, Joffe A, et al. Quality of reporting in systematic reviews of adverse events: systematic review. BMJ. 2014;348:f7668 10.1136/bmj.f7668
    1. Pieper MJ, van Dalen-Kok AH, Francke AL, van der Steen JT, Scherder EJ, Husebø BS, et al. Interventions targeting pain or behaviour in dementia: a systematic review. Ageing Res Rev. 2013;12(4):1042–55. 10.1016/j.arr.2013.05.002
    1. Galvin R, Moriarty F, Cousins G, Cahir C, Motterlini N, Bradley M, et al. Prevalence of potentially inappropriate prescribing and prescribing omissions in older Irish adults: findings from The Irish LongituDinal Study on Ageing study (TILDA). Eur J Clin Pharmacol. 2014. May;70(5):599–606. 10.1007/s00228-014-1651-8 Epub 2014 Feb 4.
    1. Aitken M, Valkova S. Avoidable costs in US Healthcare. IMS Institute for Healthcare Informatics, Parsippany, NJ, USA: 2013. Available: . Accessed 4 June 2015.
    1. Bradley MC, Fahey T, Cahir C, Bennett K, O’Reilly D, Parsons C, et al. Potentially inappropriate prescribing and cost outcomes for older people: a cross-sectional study using the Northern Ireland Enhanced Prescribing Database. European Journal of Clinical Pharmacology, 2012;68(10), 1425–1433. 10.1007/s00228-012-1249-y
    1. Patterson SM, Hughes CM, Cardwell C, Lapane KL, Murray AM, Crealey GE. A cluster randomized controlled trial of an adapted U.S. model of pharmaceutical care for nursing home residents in Northern Ireland (Fleetwood Northern Ireland study): a cost-effectiveness analysis. J Am Geriatr Soc. 2011;59(4):586–93. 10.1111/j.1532-5415.2011.03354.x Epub 2011 Mar 31. .
    1. Review of Health and Social Care Burdens. Lifting the Burdens Task Force. Local Government Association, London: 2008.
    1. Ginsburg LR, Chuang Y, Berta WB, Norton PG, Ng P, Tregunno D, et al. The relationship between organizational leadership for safety and learning from patient safety events. Health Service Research 2010;45(3),607–632.
    1. National Co-ordinating Council for Medication Error Reporting and Prevention. The First Ten Years “Defining the Problem and Developing Solutions”. United States Pharmacopia, Rockville, Maryland. 2005. Available: . Accessed 8 May 2013.
    1. Wightman R, Fielding J, Green S. Audit of antipsychotic prescribing in dementia: Cambridgeshire results and lessons learnt. Psychiatria Danubina 2011;23: S126–129.
    1. Hill KD, Wee R. Psychotropic drug-induced falls in older people: a review of interventions aimed at reducing the problem. Drugs Aging. 2012;29(1):15–30. 10.2165/11598420-000000000-00000 .
    1. Cleary A, Walsh F, Connolly H, Hays V, Oluwole B, Macken E, et al. Monitoring and documentation of side effects from depot antipsychotic medication: an interdisciplinary audit of practice in a regional mental health service. J Psychiatr Ment Health Nurs. 2011;14 10.1111/j.1365-2850.2011.01807.x
    1. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687 10.1136/bmj.g1687
    1. Riker GI, Setter SM. Polypharmacy in older adults at home: what it is and what to do about it-implications for home healthcare and hospice, part 2. Home Healthcare Nurse. 2013;31(2):65–77; quiz 78–9. 10.1097/NHH.0b013e31827f43b2
    1. Audit Commission. A Spoonful of Sugar: Medicines Management in NHS Hospitals. London, UK: The Stationery Office; 2001.
    1. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Safety 2006;29(5):385–96
    1. Heeley E, Riley J, Layton D, Wilton LV, Shakir SA. Prescription-event monitoring and reporting of adverse drug reactions. Lancet. 2001;358(9296):1872–3.
    1. Onder G, van der Cammen TJ, Petrovic M, Somers A, Rajkumar C. Strategies to reduce the risk of iatrogenic illness in complex older adults. Age Ageing 2013;42:284–91. 10.1093/ageing/aft038
    1. McKibbon KA, Lokker C, Handler SM, Dolovich LR, Holbrook AM, O’Reily D, et al. The effectiveness of integrated health information technologies across the phases of medication management: a systematic review of randomized controlled trials. Journal of the American Medical Informatics Association 2012;19: 22–30. 10.1136/amiajnl-2011-000304

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다